Evidence map›Paper›PMID 26041282›Full record

ArticleJournal of virology2015

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Lucie Fénéant, Julie Potel, Catherine François, Famara Sané, Florian Douam, Sandrine Belouzard, Noémie Calland, Thibaut Vausselin, Yves Rouillé, Véronique Descamps and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Fusion of Enveloped Viruses in Endosomes.Traffic (Copenhagen, Denmark) · 2016
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Lucie FénéantMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France.
Julie PotelMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France.
Catherine FrançoisVirology Department, EA4294 UPJV, Amiens University Hospital, Amiens, France.
Famara SanéLaboratoire de Virologie EA3610, Université Lille 2, CHRU Lille, Lille, France.
Florian DouamCNRS-UMR5557, Microbial Ecology, Université Claude Bernard Lyon 1, Villeurbanne, France.
Sandrine BelouzardMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France.
Noémie CallandMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France.
Thibaut VausselinMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France.
Yves RouilléMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France.
Véronique DescampsVirology Department, EA4294 UPJV, Amiens University Hospital, Amiens, France.
Thomas F BaumertINSERM U1110, Université de Strasbourg, Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Gilles DuverlieVirology Department, EA4294 UPJV, Amiens University Hospital, Amiens, France.
Dimitri LavilletteCNRS-UMR5557, Microbial Ecology, Université Claude Bernard Lyon 1, Villeurbanne, France.
Didier HoberLaboratoire de Virologie EA3610, Université Lille 2, CHRU Lille, Lille, France.
Jean DubuissonMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France.
Czeslaw WychowskiMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France.
Laurence CocquerelMolecular and Cellular Virology Laboratory, Center for Infection and Immunity of Lille, University Lille Nord de France, CNRS UMR8204, INSERM U1019, Pasteur Institute of Lille, Lille, France laurence.cocquerel@ibl.cnrs.fr.
Center for Infection and Immunity of Lille · FRCentre National de la Recherche Scientifique · FRInserm · FRUniversité de Lille · FRInstitut Pasteur de Lille · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledIn our study, we characterized the effect of monensin, an ionophore that is known to raise the intracellular pH, on the hepatitis C virus (HCV) life cycle. We showed that monensin inhibits HCV entry in a pangenotypic and dose-dependent manner. Monensin induces an alkalization of intracellular organelles, leading to an inhibition of the fusion step between viral and cellular membranes. Interestingly, we demonstrated that HCV cell-to-cell transmission is dependent on the vesicular pH. Using the selective pressure of monensin, we selected a monensin-resistant virus which has evolved to use a new entry route that is partially pH and clathrin independent. Characterization of this mutant led to the identification of two mutations in envelope proteins, the Y297H mutation in E1 and the I399T mutation in hypervariable region 1 (HVR1) of E2, which confer resistance to monensin and thus allow HCV to use a pH-independent entry route. Interestingly, the I399T mutation introduces an N-glycosylation site within HVR1 and increases the density of virions and their sensitivity to neutralization with anti-apolipoprotein E (anti-ApoE) antibodies, suggesting that this mutation likely induces conformational changes in HVR1 that in turn modulate the association with ApoE. Strikingly, the I399T mutation dramatically reduces HCV cell-to-cell spread. In summary, we identified a mutation in HVR1 that overcomes the vesicular pH dependence, modifies the biophysical properties of particles, and drastically reduces cell-to-cell transmission, indicating that the regulation by HVR1 of particle association with ApoE might control the pH dependence of cell-free and cell-to-cell transmission. Thus, HVR1 and ApoE are critical regulators of HCV propagation. IMPORTANCE: Although several cell surface proteins have been identified as entry factors for hepatitis C virus (HCV), the precise mechanisms regulating its transmission to hepatic cells are still unclear. In our study, we used monensin A, an ionophore that is known to raise the intracellular pH, and demonstrated that cell-free and cell-to-cell transmission pathways are both pH-dependent processes. We generated monensin-resistant viruses that displayed different entry routes and biophysical properties. Thanks to these mutants, we highlighted the importance of hypervariable region 1 (HVR1) of the E2 envelope protein for the association of particles with apolipoprotein E, which in turn might control the pH dependency of cell-free and cell-to-cell transmission.

Indexed as

Cell LineDose-Response Relationship, DrugDrug Resistance, ViralFluorescent Antibody Technique, IndirectHepacivirusHumansHydrogen-Ion ConcentrationIonophoresMonensinMutation, MissenseNeutralization TestsViral Envelope ProteinsViral ProteinsVirus InternalizationE1 protein, Hepatitis C virusglycoprotein E2, Hepatitis C virusHVR1 protein, Hepatitis C virusIonophoresMonensinViral Envelope ProteinsViral Proteins

Identifiers

PMID26041282
PMCPMC4524216
OpenAlexW1505703473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.